» Articles » PMID: 36555623

Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Dec 23
PMID 36555623
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus (HBV) and hepatitis delta virus (HDV) are highly prevalent viruses estimated to infect approximately 300 million people and 12-72 million people worldwide, respectively. HDV requires the HBV envelope to establish a successful infection. Concurrent infection with HBV and HDV can result in more severe disease outcomes than infection with HBV alone. These viruses can cause significant hepatic disease, including cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and represent a significant cause of global mortality. Therefore, a thorough understanding of these viruses and the immune response they generate is essential to enhance disease management. This review includes an overview of the HBV and HDV viruses, including life cycle, structure, natural course of infection, and histopathology. A discussion of the interplay between HDV RNA and HBV DNA during chronic infection is also included. It then discusses characteristics of the immune response with a focus on reactions to the antigenic hepatitis B surface antigen, including small, middle, and large surface antigens. This paper also reviews characteristics of the immune response to the hepatitis D antigen (including small and large antigens), the only protein expressed by hepatitis D. Lastly, we conclude with a discussion of recent therapeutic advances pertaining to these viruses.

Citing Articles

Impact of preS1 Evaluation in the Management of Chronic Hepatitis B Virus Infection.

Hayashi Y, Tajiri K, Ozawa T, Angata K, Sato T, Togayachi A Medicina (Kaunas). 2024; 60(8).

PMID: 39202615 PMC: 11356368. DOI: 10.3390/medicina60081334.


Incorporating Intracellular Processes in Virus Dynamics Models.

Ciupe S, Conway J Microorganisms. 2024; 12(5).

PMID: 38792730 PMC: 11124127. DOI: 10.3390/microorganisms12050900.


Current perspectives of viral hepatitis.

Usuda D, Kaneoka Y, Ono R, Kato M, Sugawara Y, Shimizu R World J Gastroenterol. 2024; 30(18):2402-2417.

PMID: 38764770 PMC: 11099385. DOI: 10.3748/wjg.v30.i18.2402.


Hepatitis B Vaccine: Four Decades on.

Mironova M, Ghany M Vaccines (Basel). 2024; 12(4).

PMID: 38675820 PMC: 11053833. DOI: 10.3390/vaccines12040439.


The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection.

Manea M, Apostol D, Constantinescu I Microorganisms. 2023; 11(11).

PMID: 38004743 PMC: 10673475. DOI: 10.3390/microorganisms11112731.


References
1.
Salimzadeh L, Bert N, Dutertre C, Gill U, Newell E, Frey C . PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018; 128(10):4573-4587. PMC: 6159957. DOI: 10.1172/JCI121957. View

2.
Giersch K, Dandri M . In Vivo Models of HDV Infection: Is Humanizing NTCP Enough?. Viruses. 2021; 13(4). PMC: 8065588. DOI: 10.3390/v13040588. View

3.
Fiedler M, Lu M, Siegel F, Whipple J, Roggendorf M . Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine. 2001; 19(32):4618-26. DOI: 10.1016/s0264-410x(01)00245-6. View

4.
Baig S, Alamgir M . The extrahepatic manifestations of hepatitis B virus. J Coll Physicians Surg Pak. 2008; 18(7):451-7. DOI: 07.2008/JCPSP.451457. View

5.
Sullivan L, Nguyen T, Harpur C, Stankovic S, Kanagarajah A, Koutsakos M . Natural killer cell receptors regulate responses of HLA-E-restricted T cells. Sci Immunol. 2021; 6(58). DOI: 10.1126/sciimmunol.abe9057. View